Why was recombinant insulin an important milestone in genetic engineering?
The development of recombinant human insulin was a landmark achievement in genetic engineering because it marked the first time a clinically significant, synthetic human protein was successfully brought to market as a pharmaceutical product.1
Prior to this 1982 milestone, patients with diabetes relied on insulin extracted from the pancreases of cows and pigs. While these animal-derived treatments were effective, the ability to use recombinant DNA technology to instruct Escherichia coli bacteria to produce insulin identical to that found in the human body represented a major leap in medical science.123
By synthesizing the specific DNA sequence that codes for human insulin and incorporating it into bacterial cells, researchers were able to overcome the limitations of natural supply and create a reliable, scalable production process. This innovation validated the potential of laboratory-engineered organisms to manufacture essential human proteins, paving the way for the modern biotechnology industry and the development of numerous other recombinant therapies.1